¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Behavioral Risk Factor Surveillance System"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® sympathetic nervous system ÇÑ±Û ±³°¨½Å°æ°è
¼³¸í   
  ÀÚÀ²½Å°æ°èÀÇ ÀÏÁ¾À¸·Î ³»Àå±â´ÉÀ» ÁַΠÇ×Áø½ÃÄѠȰµ¿À» Áõ°¡½Ã۴ ±â´ÉÀ» °¡Áø´Ù. ÀÚÀ²½Å°æ°èÀÇ ´Ù¸¥ °è¿­ÀΠºÎ±³°¨½Å°æ°è´Â ¹Ý´ë·Î ³»Àå±â´ÉÀ» ¾ïÁ¦½ÃÄÑ ¿¡³ÊÁö¸¦ ºñÃàÇϴ ±â´ÉÀ» °¡Áø´Ù. ÀÚÀ²½Å°æ°èÀÇ ÇØºÎÇÐÀû Æ¯¼ºÀº ½Å°æÀÌ ÁßÃ߽Űæ°è¿¡¼­ ³ª¿Í ¸ñÇ¥Àå±â¿¡ µµ´ÞÇϱâ Àü¿¡ ÇѹøÀÇ ½Ã³À½º(synapse)¸¦ ÀÌ·é´Ù´Â Á¡À̸ç, µû¶ó¼­ ÀÚÀ²½Å°æ°è´Â µÎ °³ÀÇ ½Å°æ(½Ã³À½º¸¦ ÀÌ·ç±â ÀüÀÇ ÀýÀü½Å°æ°ú ÀÌ·é ÈÄÀÇ ÀýÈĽŰæ)À¸·Î ±¸¼ºµÈ´Ù. ÀÚÀ²½Å°æ°èÁß ±³°¨½Å°æ°è´Â ÁßÃ߽Űæ°è Áï Ã´¼ö ºÎ±ÙÀÇ ±³°¨½Å°æÀý(sympathetic ganglion)¿¡¼­ ½Ã³À½º°¡ ÀϾ°í, ºÎ±³°¨ ½Å°æ°è´Â ÁßÃ߽Űæ°è¿¡¼­ ¸Ö¸® ¶³¾îÁø ¸ñÇ¥ Àå±âºÎ±ÙÀÇ ½Å°æÀý(ganglion)¿¡¼­ ½Ã³À½º°¡ ÀϾ´Â Á¡ÀÌ ´Ù¸£´Ù.
¿µ¹® musculoskeletal System ÇÑ±Û ±Ù°ñ°Ý°è
¼³¸í   
  ±ÙÀ°°ú À̵頱ÙÀ°ÀÌ ºÙ¾î¼­ °°À̠Ȱµ¿À» ¼öÇàÇϴ °ñ°Ý(»À¸¦ ÅëÅо»ÇÔ)À» ÇÔ²² ºÎ¸£´Â ¸». µû¶ó¼­ ¿©±âÀÇ ±ÙÀ°Àº ¸ðµÎ °¡·Î¹«´Ì±Ù¿¡ ¼ÓÇϸç, ¼öÀÇÀûÀ¸·Î ¿òÁ÷ÀÏ ¼ö ÀÖ´Ù.
¿µ¹® muscular system ÇÑ±Û ±ÙÀ°°èÅë
¼³¸í   
  ±ÙÀ°¿¡ ÀÇÇØ ÀÌ·ç¾îÁø ÇϳªÀÇ °èÅëÀ» ÀÓÀÇÀûÀ¸·Î ³ª´©¾î ºÎ¸¥ ¸».
¿µ¹® male reproductive system ÇÑ±Û ³²¼º»ý½Ä±â°è
¼³¸í   
  ³²¼ºÀÇ »ý½Ä±â´Â ¿©·¯ ±â°üÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. °íȯ, ºÎ°íȯ, Á¤°ü, Á¤³¶, Àü¸³»ù, ¿ÜºÎ¼º±â(À½°æ) µîÀ¸·Î ±¸¼ºµÇ´Âµ¥, ½ÇÁ¦ÀûÀ¸·Î Á¤ÀÚ¸¦ »ý¼ºÇϴ °÷Àº ´Ü ÇÑ °÷ °íȯ»ÓÀ̸ç, ³ª¸ÓÁö ±â°üÀº À̸¦ µ½´Â ±â´ÉÀ» ¼öÇàÇϰí ÀÖ´Ù. Á¤Àڴ °íȯÀÇ Á¤¼¼°üÀ̶õ °÷¿¡¼­ ¸¸µé¾îÁø µÚ¿¡ ¹ÛÀ¸·Î ³ª¿Í ±ä ¿©Á¤À» ½ÃÀÛÇϰԠµÈ´Ù. ±× µÚ ºÎ°íȯÀ» Áö³ª Á» ´õ ¼º¼÷ÇØ Áø µÚ¿¡ Á¤°ü¿¡¼­ Á¤³¶ÀÇ ºÐºñ¹°°ú ¸¸³ª°í ´Ù½Ã ¿äµµ·Î ³ª°¡°Ô µÈ´Ù. À̶§ ¿äµµ µÚÂÊ¿¡ À§Ä¡Çϴ Àü¸³»ùÀÇ ºÐºñ¹°ÀÌ ÇÕÃÄÁö°Ô µÇ°í ÀÌ Á¤¾×Àº ¿ÜºÎ¼º±â¸¦ °ÅÃļ­ ¹ÛÀ¸·Î ³ª°¡°Ô µÈ´Ù.
  
  ³²¼º»ý½Ä±â°è
¿µ¹® lymphatic system ÇÑ±Û ¸²ÇÁ°è
¼³¸í   
  ´ë°³ ¸Æ°ü°è¶ó°í Çϸé, Ç÷°ü°è¿Í ¸²ÇÁ°ü°è¸¦ ÇÕÃļ­ ¸»ÇÑ´Ù. ÀÌÁß¿¡ ¸²ÇÁ¿¡ ÀÇÇØ ÀÌ·ç¾îÁö´Â ÇϳªÀÇ °èÅëÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • empiric risk
    °æÇèÀûÀ§Çèµµ
  • high risk group
    °íÀ§Ç豺
  • high risk patient
    °íÀ§ÇèȯÀÚ
  • low risk group
    ÀúÀ§Ç豺
  • physical hazard risk
    ¹°¸®ÀûÀ¯ÇØÀ§Çèµµ
  • population attributable risk
    ¸ðÁý´Ü±âÀÎÀ§Çèµµ
  • relative risk
    »ó´ëÀ§Çèµµ
  • relative risk ratio
    »ó´ëÀ§Çèºñ
  • radiation risk coefficient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • risk
    1. À§Çè 2. À§Çèµµ
  • risk assessment
    À§ÇèµµÆò°¡
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • risk benefit ratio
    À§ÇèÆíÀͺñ
  • risk difference
    À§ÇèµµÂ÷ÀÌ
  • risk management
    À§Çèµµ°ü¸®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • central nervous system
    ÁßÃ߽Űæ°è, ÁßÃ߽Űæ°èÅë
  • information system
    Á¤º¸Ã¼°è
  • lymphatic system
    ¸²ÇÁ°èÅë
  • nervous system
    ½Å°æ°è, ½Å°æ°èÅë
  • open system
    1. °³¹æÁ¦, 2. °³¹æÇüº´¿ø
  • peripheral nervous system
    ¸»ÃʽŰæ°è, ¸»ÃʽŰæ°èÅë
  • registration system
    ½Å°íÁ¦µµ, µî·ÏÁ¦µµ
  • reproductive system
    »ý½Ä°èÅë
  • respiratory system
    È£Èí°èÅë
  • reticuloendothelial system
    ±×¹°³»ÇǰèÅë, ¼¼¸Á³»ÇǰèÅë
  • stereotactic system
    Á¤À§°íÁ¤±â
  • urinary system
    ºñ´¢°èÅë
  • factor
    ÀÎÀÚ, ¿äÀÎ, °è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • surveillance
    ¿ªÇаü¸®Á¤º¸Á¶»ç
  • absolute risk
    Àý´ëÀ§Çè, Àý´ëÀ§Çèµµ
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • acceptable risk
    Çã¿ëÀ§Çè, Çã¿ëÀ§Çèµµ
  • anesthetic risk
    ¸¶ÃëÀ§Çèµµ
  • attributable risk
    ±â¿©À§Çèµµ
  • risk assessment
    À§ÇèµµÆò°¡
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • benefit/risk ratio
    À¯ÀÍÀ¯ÇغñÀ²
  • radiation risk coefficient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • risk difference
    À§ÇèµµÂ÷ÀÌ
  • explosion risk
    Æø¹ßÀ§Çèµµ
  • relative risk estimation
    »ó´ëÀ§ÇèµµÃßÁ¤
  • high risk group
    °íÀ§Çèµµ±º
  • lifetime risk
    Æò»ýÀ§Çèµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high risk infant
    °íÀ§Ç輺 ¿µ¾Æ.
  • physical hazard =p. risk
    ½ÅüÀû À§Çè (ÊÙËøËôÌ´).
  • physical risk =physical hazard
    ½ÅüÀû À§Çè(µµ)(ËàÌ§ËøËô̴̬)
  • radiation risk
    ¹æ»ç¼±À§ÇØ, ¹æ»ç¼± À§Çè
  • radiation risk coeffecient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • recurrence risk
    Àç¹ßÀ§Çè
  • relative risk
    ºñ±³À§Çèµµ(ËÓË´Ëô̴̬).
  • relative risk
    ºñ±³À§Çèµµ
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • F factor (fertility factor)
    FÀÎÀÚ, ¼öÅÂÀÎÀÚ
  • ABH system
    ABH °è(Åë)
  • ABO blood group system
    ABOÇ÷¾×Çü°è(Åë).
  • ABO blood group=ABO system
    ABO Ç÷¾×Çü
  • Apgar scoring system
    Apgar Á¡¼öÆò°¡¹ý
  • Bactec system
    ¹ÚÅØ°èÅë
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • behavioral approach
    ÇൿÀû Á¢±Ù
  • behavioral dependence
    ÇൿÀÇÁ¸
  • behavioral deviation
    ÇൿÀÏÅ»
  • behavioral genetics
    ÇൿÀ¯ÀüÇÐ(ú¼ÔÑë¶îîùÊ).
  • behavioral group therapy
    Áý´ÜÇൿġ·á(¿ä¹ý)
  • behavioral modification
    Çൿ¼öÁ¤
  • behavioral observation audiometry
    Çൿ°üÂûû·Â°Ë»ç
  • behavioral science
    Çൿ°úÇÐ(ú¼ÔÑΡùÊ)
  • behavioral side effects
    ÇൿºÎÀÛ¿ë
  • behavioral therapy
    Çൿġ·á, Çൿ¿ä¹ý(ú¼ÔÑèþÛö)
  • behavioral toxicity
    Çൿµ¶¼º(ú¼ÔÑÔ¸àõ)
  • cognitive-behavioral therapy
    ÀÎÁö-Çൿ ¿ä¹ý(ìãò±ú¼ÔÑèþÛö)
  • modification, behavioral
  • postencephalitic behavioral syndrome
    ³ú¿°ÈÄ ÇൿÁõÈıº
  • absolute risk
    Àý´ëÀ§Çè
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • digestive system
    ¼ÒÈ­(á¼ûù)½Ã½ºÅÛ
  • DNA replicase system
    DNA ·¹Çø®ÄÉÀ̽º ½Ã½ºÅÛ (ÔÒ) replisome
  • ecological system
    »ýÅÂÇÐÀû(ßæ÷¾ùÊîÜ) ½Ã½ºÅÛ
  • electron transfer system
    ÀüÀÚÀü´Þ(ï³í­îîÓ¹) ½Ã½ºÅÛ
  • electron transport system
    ÀüÀÚ¼ö¼Û(ï³í­âÃáê) ½Ã½ºÅÛ
  • endocrine system
    ³»ºÐºñ¼±(Ò®ÝÂù²àÊ) ½Ã½ºÅÛ
  • endomembrane system
    ³»¸·(Үد) ½Ã½ºÅÛ
  • energy-regenerating system
    ¿¡³ÊÁö Àç»ý(î¢ßæ) ½Ã½ºÅÛ
  • enzyme system
    È¿¼Ò (ý£áÈ) ½Ã½ºÅÛ
  • extrinsic system
    ¿ÜÀÎ(èâì×) ½Ã½ºÅÛ
  • FAS system
    FAS ½Ã½ºÅÛ
  • fatty acid synthetase system
    Áö¹æ»ê ÇÕ¼º È¿¼Ò(ò·Û¸ß«ùêà÷ý£áÈ)½Ã½ºÅÛ
  • genetic system
    À¯Àü(ë¶îî) ½Ã½ºÅÛ
  • host-guest system
    ÁÖ-°´(ñ«-ËÔ) ½Ã½ºÅÛ
  • hydrogen transport system
    ¼ö¼Ò ¼ö¼Û(â©áÈâÃáê) ½Ã½ºÅÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • conventional film screen system
    ±âÁ¸Çʸ§Ã¼Áµ
  • digestive system
    ¼ÒÈ­±â°èÅë
  • display system
    Ç¥½ÃÀåÄ¡
  • DOS [=disk operating system]
    µð½ºÅ©¿î¿µÃ¼Á¦
  • electronically steered system
    ÀüÀÚÁ¶ÇâÀåÄ¡
  • hospital information system(HIS)
    º´¿øÁ¤º¸È­Ã¼°è
  • lymphatic system
    ¸²ÇÁ°è
  • OCS(order communication system)
    ó¹æÀü´Þü°è
  • operating system [=OS]
    ¿î¿µÃ¼°è
  • OS [=operating system]
    ¿î¿µÃ¼Á¦
  • PACS [=picture archiving and communicating system]
    ÆÑ½º, ¿µ»óÀúÀå ¹× Àü¼Ûü°è
  • portal system
    ¹®¸Æ°è
  • radiologic information system(RIS)
    ¹æ»ç¼±°ú Á¤º¸È­Ã¼°è
  • real time system
    ½Ç½Ã°£Ã¼°è
  • reproductive system
    »ý½Ä±â°èÅë
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PF pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid...
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
CRI Cardiac Risk Index; catheter-related infection; chronic renal insufficiency; chronic respiratory ins...
HRP high-risk patient; high-risk pregnancy; histidine-rich protein; horseradish peroxidase
IRIS integrated risk information system; interleukin regulation of immune system; International Research ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BIS Behavioral Inhibition System
PRAMS Pregnancy Risk Assessment Monitoring System
SENSOR Sentinel Event Notification System for Occupational Risk
ABLES Adult Blood Lead Epidemiology and Surveillance program
CDSC Communicable Disease Surveillance Centre
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • behavioral dentistry
    Çൿ Ä¡°úÇÐ
  • behavioral disorder
    Çൿ Àå¾Ö
  • behavioral modification
    Çൿ º¯Çü, Çൿ ¼öÁ¤
  • behavioral reinforcement
    Çൿ °­È­
  • behavioral science
    Çൿ °úÇÐ
  • behavioral therapist
    Çൿ Ä¡·áÀÚ
  • cognitive behavioral intervention
    ÀÎ½Ä Çൿ Á¶Àý
  • cognitive-behavioral management
    ÀνÄ-Çൿ Á¶Àý
  • Millon Behavioral Health Inventory
    Millon Çൿ °Ç°­ °Ë»ç, ¹Ð·Ð ÇൿÀû °Ç°­°Ë»ç
  • postencephalitic behavioral syndrome
    ³ú¿°ÈÄ Çൿ ÁõÈıº
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • ABO blood group system
    ABO Ç÷¾×Çü°è, ABO Ç÷¾×Çü °èÅë
    A, B´Â ¿ì¼º, O´Â ¿­¼ºÀ¸·Î¼­, A, B, AB, OÇüÀÌ ÀÖ´Ù.
  • ABO system
    ABO Çü, ABO °èÅë
  • achromatic system
    ¹«»ö°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
glaucoma, risk factors If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites).
(12 Dec 1998)
relative risk <epidemiology> The proportion of diseased people amongst those exposed to the relevant risk factor divided by the proportion of diseased people amongst those not exposed to the risk factor. This should be used in those cohort studies where those with and without disease are followed to observe which individuals become diseased.
(05 Dec 1998)
risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
(12 Dec 1998)
risk assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences.
(12 Dec 1998)
risk benefit An analysis of risk versus benefit is a complex assessment that must be made by a physician prior to the administration of a particular form of drug therapy. Since many medications may have side effects that can be harmful (during the course of treatment), the overall risk of a particular form of drug therapy must be weighed against the overall threat of the untreated disease process (or treatment with an altenative drug).
(27 Sep 1997)
risk factors An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
(12 Dec 1998)
risk management The process of minimizing risk to an organization by developing systems to identify and analyze potential hazards to prevent accidents, injuries, and other adverse occurrences, and by attempting to handle events and incidents which do occur in such a manner that their effect and cost are minimised. Effective risk management has its greatest benefits in application to insurance in order to avert or minimise financial liability.
(12 Dec 1998)
risk of recurrence In medical genetics, the chance that a genetic (inherited) disease present in a family will recur in that family. The concept in general medicine means the chance that an illness we come back again.
(12 Dec 1998)
risk patient Patient who is at risk, because of his/her behaviour or because of the type of person he/she is.
(18 Nov 1997)
risk reduction Techniques used to reduce your chances of getting a certain cancer. For example: reducing your dietary fat may help prevent breast cancer.
(09 Oct 1997)
risk-taking Undertaking a task involving a challenge for achievement or a desirable goal in which there is a lack of certainty or a fear of failure. It may also include the exhibiting of certain behaviours whose outcomes may present a risk to the individual or to those associated with him or her.
(12 Dec 1998)
competing risk An event that removes a subject from being at risk for an outcome under investigation.
(05 Mar 2000)
pregnancy, high-risk Pregnancy in which the mother and/or foetus are at greater than normal risk of morbidity or mortality. Causes include lack of adequate prenatal care, previous obstetrical history, pre-existing maternal disease or pregnancy-induced disease, and multiple gestation, as well as advanced maternal age.
(12 Dec 1998)
health risk assessment Method of describing an individual's chance of falling ill or dying of a specified condition, based on actuarial calculations that allow for known exposure to risk; expressed as expected age at which death or disease will occur, and intended as a way of drawing an individual's attention to the probable consequences of risk behaviour.
(05 Mar 2000)
oesophageal carcinoma risk factors <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • security risk
    (Ä¡¾È»óÀÇ)À§Çè Àι°
  • war risk insurance
    ÀüÀï º¸Çè
  • factor
    ¿ä¼Ò,¿äÀÎ
  • F factor
    FÀÎÀÚ;¿°¼ºÀÎÀÚ
  • R factor
    R ÀÎÀÚ(¼¼±ÕÀÇ ¾àÁ¦ ³»¼º ÀÎÀÚ)
  • Rh factor
    ¸®¼­½º ÀÎÀÚ(ÀûÇ÷±¸ ¼Ó¿¡ ÀÖ´Â ÀÀÇ÷¼Ò)
  • Rhesus factor(antigen)
    =RH FACTOR
  • coal-factor
    ¼®Åº Áß°³ »óÀÎ(µµ¸Å »óÀÎ)
  • common factor
    =COMMON DIVISOR
  • conversion factor
    (¹®ÀÇ.ÀÚ·áû±¸¿¡¼­ ½ÇÁ¦ »óǰ±¸¸ÅÀÎÀ¸·ÎÀÇ)ÀüȯÀ²
  • factor
    ¿ä¼Ò;¿äÀÎ;¿øÀÎ;Àμö;ÀÎÀÚ;°è¼ö;À²;´ë¸®»ó;µµ¸Å»ó;Á߸ÅÀÎ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • factor cost
    ¿äÀÎ(¿ä¼­)ºñ¿ë
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á